Ca-DTPA / Zn-DTPA - hameln pharmaceuticals

American FDA approves hameln pharmaceuticals Ca-DTPA and Zn-DTPA

The FDA has approved Ca-DTPA and Zn-DTPA as part of its ongoing effort to provide the American public the best available protection against nuclear accidents and terrorists threats. Ca-DTPA and Zn-DTPA are used for treatment of internal contamination with plutonium, americium, or curium. Both products increase the rate of elimination of these radioactive materials from the body.

hameln pharmaceuticals – specialist for parenterals – is manufacturer of pentetate calcium trisodium injection (Ca-DTPA) and pentetate zinc trisodium injection (Zn-DTPA) . The approval of both products was August 11, 2004.

	The specialist for top parenteral products
treatment data form Ca-DTPA \| treatment data form Zn-DTPA\| FDA FAQ \| Zn-DTPA leaflet \| Ca-DTPA leaflet \| contact